BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 32452900)

  • 1. Pneumonitis associated with immune checkpoint inhibitors among patients with non-small cell lung cancer.
    Shannon VR
    Curr Opin Pulm Med; 2020 Jul; 26(4):326-340. PubMed ID: 32452900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.
    Naidoo J; Nishino M; Patel SP; Shankar B; Rekhtman N; Illei P; Camus P
    Clin Lung Cancer; 2020 Sep; 21(5):e435-e444. PubMed ID: 32576443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
    Nishiyama O; Shimizu S; Haratani K; Isomoto K; Tanizaki J; Hayashi H; Yamazaki R; Oomori T; Nishikawa Y; Sano A; Nakagawa K; Tohda Y
    BMC Pulm Med; 2021 May; 21(1):155. PubMed ID: 33964920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.
    Zhang Q; Tang L; Zhou Y; He W; Li W
    Front Immunol; 2021; 12():663986. PubMed ID: 34122422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case-control study.
    Ichimura T; Hinata M; Ichikura D; Suzuki S
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):21-30. PubMed ID: 34648059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
    Moda M; Saito H; Kato T; Usui R; Kondo T; Nakahara Y; Murakami S; Yamamoto K; Yamada K
    Thorac Cancer; 2020 Dec; 11(12):3576-3584. PubMed ID: 33078531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.
    Zhai X; Zhang J; Tian Y; Li J; Jing W; Guo H; Zhu H
    Cancer Biol Med; 2020 Aug; 17(3):599-611. PubMed ID: 32944393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitor-related chronic pneumonitis: a case report and literature review.
    Yuan-Di Wang ; Yuan S; Wen C; Ji Z; Xiang B; Wang B; Zhang Z
    Immunotherapy; 2023 Oct; 15(14):1117-1123. PubMed ID: 37431609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of current immune checkpoint inhibitors in non-small cell lung cancer.
    Abdayem P; Planchard D
    Expert Opin Drug Saf; 2021 Jun; 20(6):651-667. PubMed ID: 33393387
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer: Erratum.
    J Immunother; 2023 Apr; 46(3):120. PubMed ID: 36883999
    [No Abstract]   [Full Text] [Related]  

  • 11. Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis.
    Lin X; Deng J; Deng H; Yang Y; Sun N; Zhou M; Qin Y; Xie X; Li S; Zhong N; Song Y; Zhou C
    Front Immunol; 2021; 12():818492. PubMed ID: 35095920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary toxicity of systemic lung cancer therapy.
    Long K; Suresh K
    Respirology; 2020 Nov; 25 Suppl 2():72-79. PubMed ID: 32729207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer.
    Sun Y; Shao C; Li S; Xu Y; Xu K; Zhang Y; Huang H; Wang M; Xu Z
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):299-304. PubMed ID: 32757454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Many Faces of Immune Checkpoint Inhibitor-Associated Pneumonitis: 4 Case Reports.
    Mojsak D; Dębczyński M; Kuklińska B; Moniuszko-Malinowska A; Mróz RM
    Am J Case Rep; 2022 Jun; 23():e936420. PubMed ID: 35648729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients.
    Kubo T; Watanabe H; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Rai K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2020 Dec; 50(12):1447-1453. PubMed ID: 32869100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
    Chen X; Sheikh K; Nakajima E; Lin CT; Lee J; Hu C; Hales RK; Forde PM; Naidoo J; Voong KR
    Oncologist; 2021 Oct; 26(10):e1822-e1832. PubMed ID: 34251728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis.
    Wang H; Guo X; Zhou J; Li Y; Duan L; Si X; Zhang L; Liu X; Wang M; Shi J; Zhang L
    Thorac Cancer; 2020 Jan; 11(1):191-197. PubMed ID: 31762218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difficulties in differentiating between checkpoint inhibitor pneumonitis and lung metastasis in a patient with melanoma.
    Safa H; Bhosale P; Weissferdt A; Oliva ICG
    Immunotherapy; 2020 Apr; 12(5):293-298. PubMed ID: 32295435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons from the diagnosis and treatment of severe immune checkpoint inhibitor-associated pneumonia: a case report.
    Weng F; Wei J; Sang M; Gao X; Zhang P; Fu Q
    Immunotherapy; 2023 Aug; 15(12):897-903. PubMed ID: 37337737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitor-Related Pneumonitis.
    Gomatou G; Tzilas V; Kotteas E; Syrigos K; Bouros D
    Respiration; 2020; 99(11):932-942. PubMed ID: 33260191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.